Parkview Health

Parkview Health Research Repository
Pharmacy

Parkview Research Center

2020

Assessing duration of therapy recommendations based on
Clostridium difficile guidelines within the Parkview health system
Curtis Stump PharmD
Trent Towne PharmD, BCPS
Aubrey Mills PharmD

Follow this and additional works at: https://researchrepository.parkviewhealth.org/pharma
Part of the Pharmacy and Pharmaceutical Sciences Commons

Assessing duration of therapy recommendations based on Clostridium difficile
guidelines within the Parkview health system
Curt Stump, PharmD; Trent Towne, PharmD, BCPS; Aubrey Mills, PharmD
RESULTS

OBJECTIVE


The objective of this study was to evaluate the appropriateness of firstepisode CDI treatment (non-severe and severe cases) within the Parkview
health system

Table 1. Patient characteristics

RESULTS
Figure 3. Inpatient oral vancomycin regimens

BACKGROUND
 As the most commonly diagnosed diarrheal illness acquired in the hospital,
Clostridium difficile infections (CDIs) affect an estimated 453,000 individuals in
the United States yearly.1 Previous studies have established that CDI represents
a significant economic burden on the United States healthcare system, with a
total CDI-attributable cost of around $6.3 billion.2
 Prior to the 2017 update, clinical practice guidelines recommended a 14-day
treatment course for initial episodes of CDI; whereas, current guidelines
recommend a 10-day course for initial, non-fulminant episodes.3,4
 Longer durations of therapy and higher doses (250 mg or 500 mg) of oral
vancomycin for initial, non-fulminant episodes lead to increased healthcare
costs and unnecessary exposure to antibiotics.4
 Previously published data does not support the use of higher doses of oral
vancomycin for treating non-severe or severe CDI; however, these higher doses
are sometimes utilized when treating this population.5 In one retrospective
study, there was no difference found in duration of symptoms, relapse, or 30day all-cause mortality when comparing those who received 125 mg doses to
those who received 250 mg doses.
 Using the dose and duration recommended by CDI guidelines, there is potential
to reduce patient exposure while also providing cost-savings to the health
system.

Table 2. Excess cost associated with using higher dose oral vancomycin regimens

DISCUSSION & CONCLUSIONS
Figure 1. Overall duration of therapy for CDI treatment

METHODS
 Study design: a retrospective chart review of patients admitted to any Parkview
hospital from March 1, 2019 to March 1, 2020 diagnosed with a first episode of
either non-severe or severe CDI
 Inclusion criteria: patients age 18 years or older hospitalized with a first episode
of non-severe or severe CDI, confirmed by the presence of laboratory and
clinical criteria
 Exclusion criteria: patients who did not meet lab or clinical criteria for CDI
diagnosis; patients who did not receive inpatient antibiotics; patients with
subsequent visits during the time period; patients who passed away during
hospitalization or shortly after and were therefore unable to complete
treatment
 Primary outcome: the percent of patients that received an appropriate total
duration of treatment, including both inpatient and outpatient therapy, defined
as a total duration greater than or equal to nine, but not including or exceeding
eleven days
 Secondary outcomes: evaluation of the primary endpoint (using the overall
population) based on different patient characteristics, and a cost analysis with
oral vancomycin

Figure 2. Overall duration of therapy based on various characteristics

 Regardless of CDI severity, it was found that most therapies were considered
inappropriate in length. Upon further analysis, it was determined that 230/374
(61.5%) of cases were too long in duration and 33/374 (11.7%) were too short.
 When evaluating specific subgroups of patients, it was found that those age 65
years or older were more likely than younger patients to have appropriate
durations of therapy. It was found that 151/228 (66.2%) of patients receiving
broad-spectrum antibiotics received longer durations of therapy, compared to
only 79/146 (54.1%) in the group that had not received broad-spectrum
antibiotics. This finding may reflect the difficulty that providers face when
determining treatment durations in this population, as clinical practice guidelines
lack evidence to make a strong recommendation.4
 It was found that almost one-third of the population received multiple strengths
of vancomycin during hospitalization, leading to excess cost.
 This study has several key limitations, including its retrospective nature, small
population examined, and reliance on previous laboratory data or documentation
to determine CDI episode.
 In this retrospective study, it was found that a majority of first episodes of CDI
were treated for an inappropriate duration, with most of those being longer than
what clinical practice guidelines recommend. While the excess cost of higher
doses of oral vancomycin may seem small, these costs may add up while also
unnecessarily increasing the risk of adverse events patients may experience.
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